Objective: To determine the effect of rimonabant on energy expenditure (O 2 consumption) in rats at different metabolic states and in cannabinoid CB1 receptor-deficient (CB1R À/À ) mice. Design: Animals were exposed to light-dark cycles and fed only during dark cycles. Rimonabant or vehicle was administered together with food (absorptive), following overnight feeding (postabsorptive) or following a whole day of no food (fasting). Indirect calorimetric measurements, physical activity and food intake were measured continuously. Results: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg À1 rimonabant showed an 18 and 49% increase in O 2 consumption, respectively after 3 h. A second dose of rimonabant administered 9-14.5 h after the first one failed to affect O 2 consumption, suggesting the development of tolerance. Similarly, stereotypic behaviors and ambulatory activity increased following the first dose but these effects were not observed after the second dose. Respiratory quotients revealed no effect of rimonabant on rates of carbohydrate and fat oxidation. Analysis of the correlation between O 2 consumption and physical activity indicated that factors other than increased physical activity may contribute to the increase in O 2 consumption. Similar studies in mice demonstrated that wild type but not CB1R À/À mice showed a change in O 2 consumption and physical activity following rimonabant administration, suggesting that these effects are mediated by the cannabinoid CB1 receptor. Conclusion: Previous studies suggested that reduced food intake alone may not explain the weight reduction observed with rimonabant. Our studies suggest that rimonabant stimulates significant acute energy expenditure in non-obese rodents, which could not be completely accounted for by an increase in physical activity. However, with the observation that there is rapid development of tolerance, these results suggest that there may be additional mechanism(s) that lead to weight loss in these rodents.
Introduction
The endocannabinoid system, which consists of cannabinoid receptors, endocannabinoids, and the enzymes involved in the biosynthesis and degradation of endocannabinoids, is involved in a wide range of physiological functions. 1 The demonstration that the endocannabinoid system plays an important role in the control of food intake offers opportunities for the treatment of obesity. 2 Antagonists of the cannabinoid receptor type 1 (CB1) display appetite-suppressant effects. 2 Rimonabant is one such antagonist that is highly specific and has been shown to be a potent appetite suppressant. 3, 4 Its weight-reducing effects have been demonstrated in various rodent models, [5] [6] [7] [8] [9] and recent large clinical trials in obese patients have shown that rimonabant reduces body weight and cardiometabolic risk factors. [10] [11] [12] [13] [14] Although reduction of food intake is considered to be the main mode of action for the weight-reducing effect of rimonabant, several studies have suggested that other metabolic processes may also be involved. 1, 15 In studies in which diet-induced as well as genetically obese (ob/ob) mice were treated with rimonabant for 3 and 7 days, respectively, body weight was reduced in comparison to pair-fed control animals. 7, 16 By contrast, rimonabant-treated obese (fa/fa)
Zucker rats 9 and diet-induced obese rats 17 did not exhibit greater weight loss compared with pair-fed obese animals, suggesting that in these animal models drug-induced weight loss could be explained by reduced food intake.
Data on the direct effect of rimonabant on energy expenditure are scarce. In genetically obese mice (ob/ob) treated with rimonabant for 7 days, O 2 consumption after 22 h following the last dose showed an increase. 16 Recently, it has been shown that AVE1625, a new CB1 receptor antagonist increased energy expenditure independent of physical activity and also increased fat oxidation in nonobese rats. 18 Furthermore, although some studies show that rimonabant increases stereotypic behaviors, such as scratching and grooming in mice and rats, 9, [19] [20] [21] data on whether rimonabant increases locomotor (ambulatory) activity, an energy-consuming behavior, appear to be controversial. 19, [22] [23] [24] Thus, the objective of the current studies was to determine whether rimonabant stimulates an increase in energy expenditure in lean rodents that is sufficiently sustained to contribute to the described weight-reducing properties of the drug.
Materials and methods

Animals
Male Sprague-Dawley (SD) rats (10 to 12 weeks old and weighing 340-380 g) were obtained from Charles River, Lyon, France. Cannabinoid CB1 receptor-deficient mice (CB1R À/À ) (6-month-old and weighing 26.5 ± 1.0 g) and their
wild-type littermates (CB1R þ / þ ) (weighing 28.0 ± 1.5 g) were obtained from an in-house breeding colony. Breeding and genotyping were performed as described previously. 25 We certify that institutional and governmental regulations concerning the ethical use of animals were followed during this research.
Experimental designs
In general, animals were housed in groups of two in cages that were maintained at 22 1C with fixed 12 h light-dark cycle (0600-1800 h lights-on). They were supplied with tap water and a standard powdered chow (KLIBA NAFAG, Kaiseraugst, Switzerland), with protein, fat and carbohydrate providing 22.3, 12.3 and 65.4% of energy, respectively. For the determination of baseline food intake and indirect calorimetric measurements, animals were caged individually.
Baseline food intake of individual animals was determined during the week preceding indirect calorimetric measurements by providing animals with powdered food and tap water ad libitum during the lights-off period (1800-0600 h), and animals were accustomed to oral administration of tap water twice daily for 3-4 days. Subsequently, weightmatched animals were grouped into eight and adapted to the respiratory chambers for 24-36 h, during which food was supplied only during the lights-off period.
During indirect calorimetric measurements food supply in the lights-off period was restricted to 70% of baseline intake to ensure that all food provided would be eaten during the night before treatment. Indirect calorimetric parameters (O 2 consumption and CO 2 production), physical activity and food intake were measured continuously (described below). O 2 consumption and physical activity were continuously measured, beginning at 1800 h on the day before administration until 1700 h the day after administration (that is, 9 h after the administration).
Rimonabant administration
Indirect calorimetry and physical activity measurements Consumption of O 2 and CO 2 production of individual animals were measured in an open-circuit indirect calorimetric system consisting of one pair of air analyzers and eight airtight respiratory chambers for both rats and mice (Oxymax Equal Flow System, Columbus Instruments, OH, USA). Each chamber was equipped with an infrared system (OPTO-M3, Columbus Instruments, OH, USA), which consisted of two rows of twelve infrared beams at two levels above the bottom of the cage (2.5 cm between individual beams) to record physical activity of the animals. Conditioned fresh air with a temperature of 28±0.5 1C and relative humidity of 50 ± 5% was pumped into the respiratory chambers at a flow rate of either 2 l min À1 (rats) or 0.6 l min À1 (mice). In each measuring cycle of 18 min, air was sequentially sampled at a flow rate of 0.4 l min À1 and analyzed by taking samples from inflow air for 2 min followed by samples of exit air from each chamber. Samples were drawn through 
Measurements of stereotypic behavior
Stereotypic behaviors associated with elevation of physical activity such as scratching (bursts of numerous rapid scratches), head shakes, wet dog shakes, yawning and penile erections) were categorized and scored 1 h after administration by watching the animals and counting stereotypic behaviors in the respiratory chambers for 15 min. Scoring was performed by investigators (one for two animals) who had no knowledge of the treatment.
Statistical analysis
Results are given as mean ± standard error of the mean (s.e.m. , respectively (Figure 1a ). By contrast, control rats showed a typical diurnal pattern of O 2 consumption with increased values during the lights-off period (Figures 1a and b) . There was no significant increase in O 2 consumption (P ¼ 0.69) in response to the second dose of rimonabant administered after 9 h (1700 h) in the fasted rats compared with vehicle-treated controls (Figure 1a) .
Similarly, rats administered the first oral dose of rimonabant (10 mg kg À1 ) during the fed state (before the onset of the lights-off period, group IV) exhibited a significant increase in O 2 consumption (Po0.005). Mean O 2 consumption calculated for 3 h after the first dose increased by 32% relative to baseline (0-2 h before drug administration) in these rats. However, response to the second and third doses administered at 0800 and 1700 h the next day (14.5 and 23.5 h, respectively after the first dose) were comparable to group II and III (Figure 1b) .
All groups of animals had low physical activity during the lights-on period (before drug administration). During the lights-off period rats receiving vehicle (groups I, II and III) increased activity by about three times and those receiving rimonabant (group IV) by about five times (Student's t-test, Po0.005 for the comparison between the control group and group IV). Compared with controls (group I), rats that were administered their first dose of rimonabant in the postabsorptive state (groups II and III) showed a dosedependent increase in physical activity (Po0.005 for both comparisons). However, a second dose of rimonabant administered during the postabsorptive state (group IV) or in the fasted state (groups II and III) did not increase physical activity compared with control rats (data not shown).
Control rats had a typical diurnal pattern of RQ, with increased values during the lights-off period (Figure 2) . Neither a single dose of rimonabant (3 and 10 mg kg 
The second and third doses of rimonabant administered at 0800 and 1700 h did not produce additional significant decreases in RQ, although these values remained lower than those of control rats.
In this experiment, intake of rats in group IV (10.1 ± 1.1 g) was 54% lower than baseline intake (21.8±2.0 g) during adaptation to the respiratory chambers in the preceding lights-off period. Furthermore, their intake was significantly lower than that of vehicle-treated rats (16.8±1.1 g).
Tolerance development in SD rats (experiment 2)
This experiment was performed to further evaluate the development of tolerance following the first administration of rimonabant that was observed in experiment 1. Rats that were administered two consecutive doses of rimonabant had a significant increase in both O 2 consumption (ANOVA and Dunnett's post hoc test, Po0.005) and physical activity (Po0.0001) only after the first administration (Figures 3a  and b) . The second dose, administered 8 h later, had no effect on either parameter. Administration of a single dose of rimonabant at fasted state (group II) also increased O 2 consumption and physical activity. Relative to baseline (0-2 h before drug administration), the increase in mean ), rats showed a significant increase in the number of scratching and wet dog shakes compared with control animals (Table 1) . By contrast, no appreciable increase in the frequency of head shakes, yawnings and penile erections was observed. Furthermore, there was no apparent increase in any of the stereotypic behaviors after the administration of the second dose of rimonabant ( þ / þ but not CB1R À/À mice (Figure 4a ). The mean O 2 consumption calculated for 3 h after drug administration in CB1R þ / þ mice was increased by 50% relative to baseline (0-2 h before drug administration). The effect of rimonabant on O 2 consumption was more prolonged than its effect on physical activity (Figure 4b ). Rimonabant did not have any effect on RQ in either CB1R þ / þ or CB1R À/À mice (data not shown).
Discussion
Although reduction in food intake is known to be the main mechanism by which rimonabant functions in decreasing weight gain, other mechanisms might also be involved. Our studies show that a single administration of rimonabant to non-obese rats and mice increases O 2 consumption in a dosedependent manner, independent of the metabolic state. This was paralleled by a simultaneous increase in physical activity and frequency of some stereotypic behaviors, consistent with previous observations. 20, 21 Regression analysis of the relationship between O 2 consumption and physical activity suggests that although the increase in physical activity could explain some of the increase in O 2 consumption, our results suggest the possible involvement of other mechanisms. As our studies were performed with only four rats, future studies with a larger number of animals will need to be performed to confirm these results. However, similar results were presented in a recent study by Herling et al. 18 In this study, which had a similar design as ours, lean Wistar rats were administered another CB1 receptor antagonist, AVE162, once daily. These authors also reported an increase in energy expenditure independent of physical activity. However, unlike our observations in SD rats, they reported no difference in physical activity between control rats and those given AVE1625. Furthermore, their results showed that Rimonabant effect on energy expenditure I Kunz et al a single administration of AVE162 at the beginning of the light period results in an increase in fat oxidation whereas we did not observe this change. These results suggest that the two compounds may act via different mechanisms. Our studies on CB1R þ / þ mice also showed that the rimonabant-induced increase in O 2 consumption was not always paralleled by a corresponding increase in physical activity, further suggesting the involvement of factors other than physical activity in the stimulation of energy expenditure. As a similar effect on CB1R À/À mice was not observed, it
suggests that the rimonabant-stimulated O 2 consumption in mice is mediated by the cannabinoid CB1 receptor. The exact mechanism underlying the induction of energy expenditure by rimonabant remains to be elucidated, but there is evidence for the involvement of the endocannabinoid system. Adipose tissue expresses various secretory proteins, including leptin, tumor necrosis factor-a and adipocytokines such as adiponectin and visfatin, which have been shown to increase fat oxidation in skeletal muscle and hepatocytes 28, 29 and regulate glucose metabolism. 30 Perwitz et al. 31 reported that cannabinoid signaling directly influences expression of adiponectin and visfatin in brown and white adipose tissues, implicating its control of energy and glucose homeostasis. Furthermore, rimonabant has been shown to increase adiponectin mRNA and protein levels in overweight and obese humans 10 and in dietinduced obese mice. 6 This increase has also been shown in pre-adipocyte cultured cells treated with rimonabant. 32, 33 These observations suggest that rimonabant may affect energy expenditure via its effects on adiponectin level. However, this is still not clear since a cross-sectional study in Pima Indians failed to show a correlation between adiponectin levels and 24-h energy expenditure and RQ. 34 Alternative mechanisms for the effect of rimonabant on energy expenditure have been suggested by studies of gene expression in diet-induced obese mice, which indicate the involvement of enzymes in the b-oxidation pathway and tricarboxylic acid cycle. 35 In our study, RQ increased in rats during the fed state (lights-off period) (Figure 2a ), reflecting the increase in carbohydrate oxidation during intake of carbohydrate-rich food. During the postabsorptive state (lights-on period), there was a similar pattern of decline in RQ in all groups, regardless of rimonabant administration, reflecting the progressive increase in fat oxidation after termination of feeding. In contrast, the significant decrease in RQ in rats that were administered their first dose of rimonabant during the fed state (before lights off) compared with control animals (Figure 2b) , likely reflects the anorectic property of rimonabant leading to a delay in feeding and overall reduction of intake.
Development of tolerance has been reported previously, but published data on this topic is still contradictory. Tolerance to the anorectic property of rimonabant has been demonstrated in obese rat models and diet-induced obese mice. 6, 9, 17, 32 Development of tolerance to the behavioral and locomotion stimulation effects of rimonabant have also been reported previously. 9, 36 Contrary to these results, Liu et al., 16 reported the absence of tolerance to thermogenic stimulation in genetically obese (ob/ob) mice treated with rimonabant for 7 days with 10 mg kg À1 intraperitoneally. Our studies in SD (and Wistar) rats showed the rapid development of tolerance to the rimonabant effects on both O 2 consumption and physical activity. Our initial experiment (experiment 1) suggested that rats that were administered a second dose of rimonabant (9-14.5 h after their first dose) showed very little or no difference in O 2 consumption and no difference in physical activity compared with control animals. This was confirmed by the second experiment, which was designed specifically to address the issue of tolerance. This experiment also showed that whereas rats had increased frequency of scratching and wet dog shakes after the first administration of rimonabant, they developed tolerance to these behavioral effects of rimonabant by the second administration. It is possible that part of the difference in tolerance development in our studies and receptor levels compared to lean rats. 37 Indeed, similar to our results, development of tolerance has also been reported for the anorectic activity of rimonabant in lean rats. 5 The rapid development of tolerance that was observed in our studies support the concept that differences in the 'tone' of endoncannabinoid system exist between lean and obese animals. 1,38,39 Doyon et al. 40 recently demonstrated that development of tolerance in obese fa/fa rats was slower than in lean Fa/? rats. Following oral treatment with 10 mg kg À1 , lean rats returned to their normal food intake after 4 days whereas in the obese rats food intake remained low until 14 days. Tolerance development is probably different in humans. Rimonabant has been administered as 5 or 20 mg doses daily in large clinical trials that have lasted for 1-2 years. 12, 14 Thus far, development of tolerance to rimonabant in humans has not been reported.
In conclusion, our studies suggest that in addition to reducing appetite, rimonabant also leads to an increase in energy expenditure that may not be completely explained by a corresponding increase in physical activity. The involvement of additional factors contributing to increased energy expenditure had been suggested from previous studies but had not been demonstrated in vivo with rimonabant. Elucidating the mechanism through which rimonabant acts to increase O 2 consumption in obese animal models could pave the way for the development of new drugs to treat obesity. It will also be important to understand the mechanism of tolerance development in these animals. Rimonabant effect on energy expenditure I Kunz et al
